Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
US RNAi therapeutics company Alnylam Pharmaceuticals announced the US Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, Amvuttra (vutrisiran). 21 March 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
Swiss biopharma Idorsia has received approval from the US Food and Drug Administration for an updated label on its hypertension drug Tryvio (aprocitentan), removing the previous Risk Evaluation and Mitigation Strategy requirement. 9 April 2025
Biotechnology
Cambridge, USA-based Merida Bioscienes, a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, has announced its launch alongside a $121million financing. 9 April 2025
Pharmaceutical
Shares of USA and UK-based KalVista Pharmaceuticals fell 4% to $11.04 yesterday, despite the company revealing it has signed a licensing deal for the commercialization rights in Japan to Kaken Pharmaceutical for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). 9 April 2025
Pharmaceutical
The uveitis treatment market across seven major markets—the USA, France, Germany, Italy, Spain, the UK, and Japan—is projected to grow from $522 million in 2023 to $1.5 billion by 2033, according to a report from data analytics firm GlobalData. This marks an annual growth rate of nearly 11%. 8 April 2025
Pharmaceutical
US biopharma Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase III TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity. 8 April 2025
Pharmaceutical
At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in development for early PD, failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy. 8 April 2025
Pharmaceutical
US biotech company Vertex Pharmaceuticals has received European Commission approval to extend the use of its cystic fibrosis therapy, Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with ivacaftor. 8 April 2025
Pharmaceutical
Alzheon, a privately-held clinical-stage biopharma company, presented promising Phase III APOLLOE4 trial results for ALZ-801 (valiltramiprosate) in treating mild cognitive impairment (MCI) in APOE4 homozygous patients at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (PD). 7 April 2025
Biotechnology
South Korean clinical-stage biotech ABL Bio on Sunday announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. 7 April 2025
Biotechnology
German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza, have announced a collaboration. 7 April 2025
Latest In Brief for Alnylam Pharmaceuticals
Biotechnology
Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination of OPT-302 with Aflibercept Study) and accelerated top-line results from its second Phase III trial ShORe (Study of OPT-302 in combination with Ranibizumab) in patients with wet AMD. 31 March 2025
Latest Relevant Ones To Watch News
Swiss ophthalmic drug company Alcon today announced it has acquired a majority interest in Aurion Biotech, a privately-held US clinical-stage company developing advanced cell therapies to treat eye diseases. 27 March 2025
24 March 2025
26 February 2025
24 February 2025
21 February 2025
11 February 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze